Table 4.

Side effects were reported in 36% of the centers, with thrombosis and thromboembolic events being the most relevant. The estimated rate of side effects excluding liver enzymes alteration was 1 case per 1000 of vaccinated patients. The vaccination efficacy was rarely evaluated, and 12% of the center reported ≥1 severe infection despite the vaccination.

Side effects post vaccination (questions 9–11)		Proportion	[95%_Conf. interval]
Liver enzymes elevation		0.295	0.158	0.477
Thrombosis or thromboembolic event		0.138	0.066	0.265
Acute graft rejection		0.130	0.028	0.436
Liver related		0.095	0.016	0.407
Allergy related		0.043	0.009	0.188
Others significant adverse eventa		0.146	0.082	0.247
Total side effects (except liver enzymes elevation)		0.357	0.209	0.539
Rate of significant side effects per patientb		0.001	0.000	0.003
Efficacy assessment (questions 12–13)
Centers testing antibodies		0.252	0.065	0.621
Timing of test	2 weeks	0.062	0.010	0.310
	1 month	0.391	0.181	0.651
	3 months	0.275	0.141	0.468
	6 months	0.021	0.004	0.108
	Other	0.008	0.001	0.042
Infection post vaccine	Yes	0.221	0.072	0.508
	Severe	0.553	0.275	0.802

^a Myocardial infarction (n = 2); post-transplant lymphoproliferative disease (n = 2); cholangitis (n = 1); Guillain Barré (n = 1); leukopenia (n = 1); thrombocytopenia (n = 1) lymphadenitis (n = 1); retinal detachment (n = 1); menorrhagia/dysmenorrhea (n = 1); unknow (n = 1).

^b Estimation of significant side effects rate per patients based on 14 centers who specified the number of patients with side effects over 38 that reported any of them.